Spots Global Cancer Trial Database for progesterone receptor positive
Every month we try and update this database with for progesterone receptor positive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC | NCT00134680 | Metastatic Brea... | Letrozole Trastuzumab | 18 Years - | Duke University | |
| Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer | NCT00365599 | Breast Cancer | suberoylanilide... tamoxifen citra... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer | NCT03042897 | Estrogen Recept... Obesity Progesterone Re... Stage I Uterine... Stage IA Uterin... Stage IB Uterin... | Dietary Interve... Exercise Interv... Laboratory Biom... Quality-of-Life... | 19 Years - | University of Southern California | |
| Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer | NCT03042897 | Estrogen Recept... Obesity Progesterone Re... Stage I Uterine... Stage IA Uterin... Stage IB Uterin... | Dietary Interve... Exercise Interv... Laboratory Biom... Quality-of-Life... | 19 Years - | University of Southern California | |
| Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer | NCT00463489 | Breast Cancer | Lifestyle inter... Mail-based | - | Ontario Clinical Oncology Group (OCOG) | |
| Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy | NCT05069038 | Breast Cancer | Palbociclib 125... | 19 Years - | University of Nebraska | |
| Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | NCT02219789 | Estrogen Recept... Progesterone Re... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Alisertib Fulvestrant Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy | NCT05069038 | Breast Cancer | Palbociclib 125... | 19 Years - | University of Nebraska | |
| Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen | NCT00118157 | Estrogen Recept... Male Breast Car... Progesterone Re... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Laboratory Biom... Lapatinib Ditos... Tamoxifen Citra... | 18 Years - | National Cancer Institute (NCI) | |
| Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | NCT02219789 | Estrogen Recept... Progesterone Re... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Alisertib Fulvestrant Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer | NCT00338728 | Anatomic Stage ... Estrogen Recept... KIT Positive PDGFR Positive Postmenopausal Progesterone Re... Prognostic Stag... | Imatinib Mesyla... Letrozole | - | M.D. Anderson Cancer Center | |
| Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy | NCT00556374 | Breast Cancer | Placebo Denosumab Non-steroidal a... Zoledronic Acid Standard of Car... | 45 Years - 100 Years | Amgen | |
| Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy | NCT05069038 | Breast Cancer | Palbociclib 125... | 19 Years - | University of Nebraska | |
| Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery | NCT02526498 | Ductal Breast C... Estrogen Recept... Invasive Breast... Progesterone Re... Stage IA Breast... Stage IB Breast... Stage IIA Breas... | Accelerated Par... High-Dose Rate ... Questionnaire A... | 45 Years - | Rutgers, The State University of New Jersey | |
| Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer | NCT03091842 | Cancer Survivor Central Obesity Estrogen Recept... Postmenopausal Progesterone Re... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Exercise Interv... Exercise Interv... Exercise Interv... Informational I... Laboratory Biom... Quality-of-Life... Questionnaire A... | 18 Years - | University of Southern California | |
| Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma | NCT00856050 | Leiomyosarcoma | letrozole | 18 Years - | Dana-Farber Cancer Institute | |
| Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer | NCT00463489 | Breast Cancer | Lifestyle inter... Mail-based | - | Ontario Clinical Oncology Group (OCOG) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
